Skip to main content

Advertisement

We're creating a new version of this page. See preview

  • Research article
  • Open Access
  • Open Peer Review

Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment

  • 1,
  • 2,
  • 4,
  • 3 and
  • 1Email author
BMC Cancer201717:858

https://doi.org/10.1186/s12885-017-3863-7

©  The Author(s). 2017

  • Received: 7 June 2017
  • Accepted: 23 November 2017
  • Published:
Open Peer Review reports

Abstract

Background

Well-known anti-malarial drug artemisinin exhibits potent anti-cancerous activities. In-vivo and in-vitro studies showed its anti-tumor and immunomodulatory properties signifying it as a potent drug candidate for study. The studies of mechanisms of cell movement are relevant which can be understood by knowing the involvement of genes in an effect of a drug. Although cytotoxicity and anti-proliferative activity of artemisinin is evident, the genes participating in its anti-migratory and reduced invasive effect are not well studied. The present study reports the alteration in the expression of 84 genes involved in cell motility upon artemisinin treatment in MCF-7 breast cancer cells using pathway focused gene expression PCR array. In addition, the effect of artemisinin on epigenetic modifier HDACs is studied.

Methods

We checked the functional stimulus of artemisinin on cell viability, migration, invasion and apoptosis in breast cancerous cell lines. Using qRT-PCR and western blot, we validated the altered expression of relevant genes associated with proliferation, migration, invasion, apoptosis and mammary gland development.

Results

Artemisinin inhibited cell proliferation of estrogen receptor negative breast cancer cells with fewer efficacies in comparison to estrogen receptor positive ones. At the same time, cell viability and proliferation of normal breast epithelial MCF10A cells was un-affected. Artemisinin strongly inhibited cancer cell migration and invasion. Along with orphan nuclear receptors (ERRα, ERRβ and ERRγ), artemisinin altered the ERα/ERβ/PR/Her expression status of MCF-7 cells. The expression of genes involved in the signaling pathways associated with proliferation, migration, invasion and apoptosis was significantly altered which cooperatively resulted into reduced growth promoting activities of breast cancer cells. Interestingly, artemisinin exhibited inhibitory effect on histone deacetylases (HDACs).

Conclusions

Upregulated expression of tumor suppressor genes along with reduced expression of oncogenes significantly associated with growth stimulating signaling pathways in response to artemisinin treatment suggests its efficacy as an effective drug in breast cancer treatment.

Keywords

  • Breast cancer
  • Proliferation
  • Migration
  • Invasion
  • HDACs

Background

Breast cancer, despite of early detection, new discoveries and increased awareness, remains the second leading cause of cancer related deaths in women worldwide. Although genetic and hormone oestrogen are the most important risk factors for breast cancer, factors like high iron content significantly contribute towards tumorigenesis [1–6]. Studies suggest strong co-relation of iron with various cancers [7–10]. Increased and decreased iron content in post and premenopausal women has been explored to be associated with increased breast cancer risk through pathways like oxidative stress and angiogenesis respectively. Wormwood (Artemisia annual) plant derived extract artemisinin is chemically a sesquiterpene lactone with a 1,2,4-trioxane ring system. The endoperoxide moiety of artemisinin forms free radicals on reaction with iron that is essential for cell division and proliferation. Compared with non-cancerous cells, depending on the tumor aggressiveness, cancer cells have a higher number of cell surface transferrin receptors, which pick up iron via interaction with the plasma iron-carrying protein transferrin. By virtue of a higher rate of iron uptake, cancer cells would be selectively more vulnerable to the cytotoxicity of artemisinin [11, 12]. Natural products such as artemisinin and many other have been tested for their cytotoxic effect on breast cancer cells [13–15]. Various in-vitro and in-vivo studies have been done to investigate the role of transferrin and its conjugates in iron-mediated effect of artemisinin in breast cancer [16–20]. Artemisinin derivatives and compounds bearing skeleton of artemisinin have also been investigated for their anti-cancerous effects [21–27]. Various nano-formulations of artemisinin is tested for effective artemisinin targeting breast cancer both in-vitro and in-vivo [28–36]. Also, combinational therapies have been done to study and compare the synergistic effect of artemisinin in breast cancer [37–42]. In-vivo studies show the potential benefits of artemisinin in breast cancer treatment [43–50] Pharmacokinetics and toxicity of artemisinin has also been tested in breast cancer patients during phase-I study [51–53]. Mechanisms underlying artemisinin-mediated anti-proliferative and apoptosis inducing role in breast cancer have also been explored [54–63]. Role of artemisinin in drug resistance has been studied as well [64, 65].

Role of transcription factor E2F and its target genes in the anti-proliferative activity of artemisinin in breast cancer is reported [57]. In present study, we first checked the effect of artemisinin treatment on cancer cell viability, proliferation, migration, invasion and apoptosis. We then report the involvement of relevant genes in the respective signaling pathways in an effect of artemisinin treatment. Taken together, our results demonstrate the molecular basis of anti-proliferative, migratory, invasion and apoptosis inducing effect of artemisinin in breast cancer. Also for the first time we have reported the HDAC inhibitory effect of artemisinin.

Methods

Drug

Artemisinin (C15H22O5) was a kind gift from IPCA (International pharmaceutical company, Mumbai, India). The stock solution of artemisinin was prepared in Dimethyl Sulfoxide (DMSO). The final DMSO concentration during treatment in the culture medium was maintained below 0.01%.

Cell culture

Breast cancer cell lines MCF-7, T47D and MDA-MB-231 were purchased from National Centre for Cell Sciences (NCCS), Pune, India. The MCF-7 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) whereas T47D and MDA-MB-231 cells in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin (MP Biomedicals) at 37 °C, 5% CO2 and 95% humidity. MCF10A, a kind gift from Dr. Annapoorni Rangarajan (IISC, Bangalore, India) was maintained in DMEM F12 containing horse serum supplemented with hydrocortisone, EGF, insulin, cholera toxin and penicillin-streptomycin at 37 °C, 5% CO2 and 95% humidity. The cells were grown until 70-80% confluence and then sub cultured with Trypsin-EDTA. All experiments involving treatment were performed in cells kept in phenol red free medium containing charcoal treated fetal bovine serum supplemented with penicillin-streptomycin for 48 h.

Cell viability assay

The effect of artemisinin on viability of cells was checked by 3-(4,5-Dimethylthiazol-2-yl)-2,5 Diphenyltetrazolium Bromide (MTT) assay. MCF10A, MCF-7, T47D and MDA-MB-231 cells were seeded at a density of 3 × 103 cells/well in 96 well plates. The cells were treated with different concentrations of artemisinin (500 nM, 1, 10, 50 and 100 μM) and incubated for two different time periods (12 and 24 h). After appropriate time period, 10 μL of MTT (MP Biomedical) (5 mg/mL in PBS) was added into each well and incubated at 37 °C, 5% CO2 atmospheric condition for another four hours. After incubation, the medium was removed and 100 μL of DMSO was added to dissolve thus formed formazan crystals. The solubilized crystals were then quantified by scanning the plates at 570 nm using Varioskan™ Flash Multimode Reader (Thermo Scientific). Three independent sets of experiments were performed to evaluate the effect of artemisinin. The percent viability was calculated by the formula-.

% viability = A/A0 X 100 where A0 and A are the absorbance of vehicle control and artemisinin treated cells respectively.

The IC50 value of artemisinin was calculated for different cell types using the nonlinear regression curve fit XY analysis of GraphPad prism software.

Colony forming assay

For colony forming assay 0.6 X 103 of MCF10A, MCF-7, T47D and MDA-MB-231 cells were seeded in triplicates in 12-well plate (Falcon Becton Dickinson) and after 24 h of cell attachment, the cells were treated with 1 μM of artemisinin. The plates were under incubation for 10 days at 37 °C, 5% CO2 to allow the growth of colonies (~50 cells/ colony). During long-term incubation, fresh complete growth medium with 1 μM of artemisinin was replaced after every three days. The cells were washed twice with 1X PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 2 mM KH2PO4), fixed with 10% (v/v) formalin and then stained with 0.01% (w/v) crystal violet solution. The excess stain was removed by washing with 1 X PBS. The plate was air-dried and image was captured using Gel Doc™ XR + Imager (Bio-Rad). To quantify the rate of colony formation, the stained cells in the form of colonies were dissolved in 10% (v/v) acetic acid and the absorbance was quantified at 540 nm using Varioskan™ Flash Multimode Reader (Thermo Scientific). The values is presented using the formula-.

Colony formation rate = 100% X (experimental absorbance value / control absorbance value).

Wound healing assay

1 X 104 MCF-7 cells were plated and grown up to 90% confluence in 12-well plate (Falcon Becton Dickinson). To restrict proliferation and to study only the migration of cancerous cells, the plated cells were kept in serum free media for 48 h. Cells were then scratched with a sterile 200 μL pipette tip (two vertical and two horizontal lines) in each well. The cells were washed twice with 1X PBS and the image was captured such as cells at stage 1 that is 0 h. Cells were treated with 1 μM artemisinin. Images of the cells undergoing migration were then taken at different time points at a magnification of 4X. Quantitation of migrated cells was done by calculating the decrease in area at all the observed time points with the help of ImageJ software.

Transwell migration and invasion assay

Transwell-migration assay was performed following manufacturer’s protocol (BD Falcon, USA). Appropriately artemisinin (1 μM, 72 h) treated MCF-7 cells were seeded at a density of 2.5 × 104 cells in upper chamber of 12 well transwell system in 500 μL of serum and phenol red free DMEM. Medium supplemented with 5% serum was used as chemoattractant in the lower chamber. After 24 h the cells on both side of the membrane were fixed with 10% formalin and stained with 0.01% crystal violet stain. The cells were scrubbed on the seeded side to quantify the percent of migrated cells only. The membrane was then washed with PBS and the cells attracted towards the serum were visualized under light microscope and pictured (10X) under different field views. The number of migrated cells in control and artemisinin treatment in 10 different fields was calculated using ImageJ software and the average value was represented in the graph. For invasion assay, the transwell migration chamber was coated with matrigel (2 mg/ml) (BD Biosciences). The cells present towards the lower side of the chamber were considered as invaded cells and were fixed and stained with crystal violet dye similar to migration assay.

Apoptosis detection assay

MCF-7 cells were seeded at a density of 5 X 104 cells/well in 35 mm plates. Further the cells were treated with 1 μM artemisinin and incubated for 24 h at 37 °C in 5% CO2. Cells were stained using a PE Annexin V Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA) according to the manufacturer’s protocol. Acquisition was performed using BD FACS Calibur (San Jose, CA, USA). 1X104 cells were analyzed using FL3 filter for 7-AAD-positive cells and FL2 filter for the PE-annexin V-positive cells. Plumbagin (5-hydroxy- 2-methyl-1, 4-naphthaquinone) was taken as positive control due to its role in induction of apoptosis at higher rate [66].

qRT-PCR array

The Human Cell Motility RT2 Profiler PCR Array purchased from Qiagen was employed to study the effect of artemisinin on genes associated with movement of cells. The array contained 84 genes including genes associated with development, growth factors, receptors important for chemotaxis and mobilization. Total RNA was isolated using Trizol from appropriately artemisinin (10 μM,72 h) treated and control MCF-7 cells. Equal amount of properly DNase I treated RNA was used to prepare cDNA using first stand cDNA synthesis kit (Invitrogen). Real time assay was performed with the array plate. mRNA level and fold change for each gene compared to control was calculated using value of cycle threshold. The alteration in the expression of genes was validated by qRT PCR and/or western blot assay. β2 microglobulin and 18S was used for normalization.

Western blot analysis

For western blot whole cell lysate of appropriately treated cells was prepared using RIPA buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4 and 1 μg/mL leupeptin]. The lysed samples were collected after centrifugation for 30 min at 12,000 rpm, 4 °C. Equal amount (40 μg) of protein was loaded after Bradford method of protein quantification. The samples were run in 10% SDS-PAGE gel, transferred on PVDF membrane (Millipore) and blocked with 5% (w/v) non-fat milk (Sigma). Blots were then incubated with primary antibody overnight [Cytochrome c (1:5000), p21 (1:5000), β catenin (1:5000), α-tubulin (1:1000), Bcl2 (1:1000), caspase 9 (1:1000, Cell Signaling), p53 (1:500, Calbiochem), p21 (Cell signaling 1:1000), E-cadherin(Cell signaling 1:1000) and HDACs (1:1000, HDAC Ab Sampler Kit, Cell Signaling)]. Thereafter, 1 h with their respective HRP conjugated secondary antibody [anti rabbit (1:5000, Sigma Aldrich) or anti mouse (1:5000, Sigma Aldrich)], the blots were then subjected to chemilumenescent detection reagent (GE Healthcare) for visualization and the bands were detected by using Gel Doc™ XR + Imager. Densitometric analyses of the protein bands was calculated by using ImageJ software.

Immunofluorescence

Cells at a density of 3 X 104 were grown in 0.2% gelatin coated coverslips in 35 mm plates. The 10 μM artemisinin treated cells were washed with ice-cold 1X PBS, fixed with methanol:acetone (1:1) and kept at -20 °C for 30 min-1 h. The cells were then blocked with blocking buffer [0.1% (w/v) bovine serum albumin, 0.3% (v/v) Triton™ X-100 in 1X PBS] for 2 h and then incubated with primary antibodies [Cytochrome c antibody (1:500, Santa Cruz), β catenin (1:5000)] overnight at 4 °C. Next day the cells were washed with TBST (1X TBST: 50 mM Tris.HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20.), then incubated with flourocrome conjugated anti-mouse antibody (1:1000, Alexa Fluor® 594, Life Technologies) for 1 h. The cells were then washed with TBST and further incubated with DiOC6 (3,3′-Dihexyloxacarbocyanine Iodide), a mitochondrial stain (1:1000, Life Technologies). Finally the coverslip was mounted on a slide using Prolong ® Gold Antifade Reagent (Life Technologies) and the images were captured using confocal microscope (Leica Microsystems CMS GmBH, Mannheim, Germany) using LAS AF application suite (Leica Application Suite Advanced Fluorescence).

Statistical analysis

Data analysis was performed by unpaired t test or by one way ANOVA using GraphPad Prism ® software where the p-values ≤0.05 were considered as significant.

Results

Reduced cell growth and colony formation of breast cancer cells upon artemisinin treatment

Cell viability assay performed using MTT suggested that during the initial stage of artemisinin treatment (12 h) there is no significant reduction in viability of the cells but after 24 h of artemisinin treatment the viability of both MCF-7 and T47D breast cancer cells was inhibited in a dose dependent manner (Fig. 1A). The effect of artemisinin as found in the breast cancer cells was not observed in normal breast epithelial cells MCF10A. When the assay was carried out in triple negative MDA-MB-231 breast cancer cells, the reduction in viability of the cells was reduced and was found to be less effective in the same range. IC50 value of artemisinin upon 24 h of treatment was found to be 60.55 μM, 32.14 μM and 88.08 μM for MCF7, T47D and MDA-MB-231 respectively. 1 μM dose of artemisinin which is physiologically relevant was used in further experiments. Next to explore the effect of artemisinin on proliferation of breast cancer cells as well as normal breast epithelial cells, clonogenic assay was performed. On the day of harvest, 50% inhibition in colony formation was observed in 1 μM artemisinin treated both MCF-7 and T47D cells while MCF10A cells remained unaffected. In MDA-MB-231 cells, 36% less colonies were detected upon artemisinin treatment (Fig. 1B).
Fig. 1
Fig. 1

Artemisinin inhibits growth and colony forming ability of estrogen receptor positive breast cancer cells. (A) Viability assay in MCF10A, MCF-7, T47D and MDA-MB-231 breast cancer cells showing the effect of artemisinin treatment in a dose and time dependent manner where artemisinin concentration is indicated in X axis and percentage viability compared to control is indicated on the Y axis. The mean + SEM for three independent experiments was calculated. Statistically significant difference was found between the absorbance of control and artemisinin treated samples ***p (<0.001), **p (<0.0078) and ns p (>0.05). B (I) Representative image of colony forming assay of artemisinin treated MCF10A, MCF-7, T47D and MDA-MB-231 breast cancer cells. (II) Graph represents mean + SEM of control, and treated samples in three separate experiments performed in triplicate, *p(<0.05), ***p (<0.001)

Artemisinin restricted breast cancer cells migration & invasion and induced apoptosis

The ability of a cancer cell to undergo rapid migration allows it to change position within the tissues. Therapeutic compounds with the ability to inhibit the motility of cancer cells are important for preventing cancer metastasis which may be achieved by a potent drug [67]. Here we have examined the effect of artemisinin on migration of MCF-7 breast cancer cells by wound healing and transwell assay. Monolayer culture of untreated MCF-7 cells, showed 50% reduction in the wound area within 48 h, whereas the reduction in the wound area was significantly less in 1 μM artemisinin treated cells. Artemisinin treated MCF-7 cells migrated at a lower rate and only one quarter of the wound was found to be healed after 96 h, whereas during that interval in untreated MCF-7 cells, about 75% percent of the wound was found to be healed (Fig. 2A I and II). When cancer cells become metastatic, it loses epithelial and gains mesenchymal characteristics which is accompanied by loss of cell-cell adhesiveness, leading to enhanced migratory capacity [68]. Transwell migration assay confirmed the anti-migratory effect of artemisinin on MCF-7 breast cancer cells (Fig. 2B I and II).
Fig. 2
Fig. 2

Artemisinin exhibits anti-migratory, anti-invasion and apoptosis inducing property in breast cancer cells. A (I) Picture represent relative cell migration in both control and treated MCF-7 cells at different time intervals. (II) Graph represents the quantification of the decrease in the area as wound healing progresses at the observed time points. Significant differences were observed between control and treated cells at different time points p (<0.0001). B (I) Image depicts the cell migration in control and artemisinin treated MCF7 cells as observed in transwell migration assay. (II) Graph depicts the average number of migrated cells. C (I) Diagram represents relative invasion in control and artemisinin treated aggressive breast cancer cells. (II) Relative invasion in depicted in the graph. D (I) Dot plot representing PE Annexin V positive, 7AAD negative MCF-7 cells after 24 h of treatment with 1 μM artemisinin, control (DMSO < 0.01%)μ and plumbagin (5 μM) as positive control. The lower left quadrants of each panels show the viable cells and 7-AAD negative, lower right quadrants represent the early apoptotic cells (PE Annexin V positive and 7-AAD negative). (II) Graph represents the percentage of early apoptotic cells in control and artemisinin treated MCF-7 cells computed from three biologically different set of experiments. Significant differences were observed between control and treated cells, *p < 0.05

One of the major hallmarks of cancer cells is their invasive property. To check the effect of artemisinin on invasive property of breast cancer cells, matrigel migration assay was performed. Significant reduced invasion was evident in MDA-MB-231 aggressive breast cancer cells (Fig. 2C I and II) upon artemisinin treatment.

Apoptosis is as a natural barrier to cancer development and serves as a marker event for chemotherapy [8, 11]. Artemisinin is reported to induce apoptosis in cancer cells. To study the involvement of genes in artemisinin-mediated apoptosis, we first validated the apoptosis inducing effect of artemisinin in MCF-7 breast cancer cells. Annexin V-PE apoptosis detection assay was carried out in control and artemisinin treated MCF-7 breast cancer cells. The flow cytometry data showed 30% increase of PE-Annexin V positive/ 7-AAD negative early apoptotic cells in artemisinin treated with respect to control MCF-7 cells (Fig. 2D I and II).

Artemisinin-mediated anti-cancerous effects is a result of alteration of relevant genes associated with cancer cell progression

In an attempt to reveal the involvement of genes in artemisinin-mediated reduced proliferation, migration, invasion and increased apoptosis, we studied the alteration of genes associated with cancer cell motility upon artemisinin treatment (10 μM, 72 h). In this study PCR array consisting of 84 genes were included. 47 genes out of 84 were found to be upregulated by more than 1.1 fold and reduced expression of 36 genes was observed. 47 upregulated genes included tumor suppressor genes such as well-known BRCA 1, BRCA2, Ras association (RalGDS/AF-6) domain family member 1 (RASSF1), GATA3, RARB, BCL2-associated agonist of cell death (BAD), MUC1 and others as shown in the Fig. 3a with the observed fold change. To validate the alteration in the genes upon artemisinin treatment we checked the expression of genes involved in mammary cell development leading to increased proliferation. Estrogen receptor alpha and beta are well studied for their effect in breast cancer progression. Reduced ERα expression and its associated anti-proliferative effect upon artemisinin is reported [59]. As orphan nuclear receptors ERRα, ERRβ, ERRγ and PgR are significantly involved in increased cancer cell proliferation [69–71], we studied their possible contribution in anti-cancerous effects of artemisinin. Reduced expression of ERRα, ERRβ, ERRγ and PgR was observed in artemisinin treated MCF-7 cells (Fig. 3b and c). At the same time increased expression of tumor suppressor ERβ [72] was found. Although expression of HER family is reported to be down-regulated in artemisinin derivative treated breast cancer cells [36], expression of oncogene HER2 was amplified in artemisinin treated cells at both RNA and protein level but at the same time HER 1 protein expression was reduced significantly. Abrogated expression of oncogenes associated with increased cell proliferation such as cyclin D1, D2 [73] GRB7 [74], AKT [75], Ki67 [76], FOXA1 [77] and Myc [78] was detected. Also, an up-regulated expression of tumor suppressors such as Rb [79], GATA3 [80] and PTEN [81] associated with cancer cell proliferation was evident (Fig. 3d and e). Significantly reduced expression of growth stimulating proteins Cyclin dependent kinases 2 and 4 were found in artemisinin treated cells. At the same time reduced p21 showed its contributing role towards artemisinin mediated reduced cell proliferation validating the previous reports. Epithelial markers such as E-cadherin are key mediators of cell–cell adhesions in epithelial tissues loss of which can promote invasiveness and metastatic behavior in many epithelial tumors [82]. In accordance with this observation, artemisinin treated cells showed enhanced expression of epithelial cell markers E-cadherin, H-cadherin and TGFβ [83], reduced level of mesenchymal proteins Twist and Slug. Reduced level of β-catenin [84] was showed in artemisinin treated cells (Fig. 3f and g). Apoptosis inducing genes BAD and P53 were found to be up regulated whereas anti-apoptotic BCL2 expression was decreased upon artemisinin treatment. Artemisinin mediated reduced invasion is a result of altered MMP2 expression as previously described [85].
Fig. 3
Fig. 3

Artemisinin alters the expression of genes associated with growth promoting activities. a Heat map showing the fold change expression of genes under study. b and c qRT PCR and western blot assay respectively showing the expression of genes associated with mammary gland development upon artemisinin treatment. d and e Respective RNA and protein expression of cell proliferation associated genes in control and artemisinin treated MCF7 cells. f and g Bar diagram and immunoblot respectively showing the expression level of proteins involved in migration, invasion and apoptosis in artemisinin treated and control cells

Increased β-catenin cytoplasmic localization contributes toward artemisinin mediated reduced cell migration

β-catenin is reported to function as an oncogene through Wnt signaling pathway. Its increased cytoplasmic localization results in reduced gene expression necessary for epithelial to mesenchymal transition. Artemisinin treatment in MCF-7 cells resulted in increased cytoplasmic β-catenin protein which indicates its contributing role towards reduced epithelial to mesenchymal transition through Wnt signaling pathway (Fig. 4a and b).
Fig. 4
Fig. 4

Cytoplasmic localization of Beta-catenin increases upon artemisinin treatment in MCF-7 breast cancer cells. a Immunofluorescence assay shows the expression and localization of beta-catenin upon artemisinin treatment. b Immunoblot against beta-catenin shows the increased cytoplasmic beta-catenin protein expression upon artemisinin treatment. α-tubulin and histone H3 used as loading control

Increased cytochrome c release and caspase 9 cleavage contributes towards artemisinin mediated increased apoptosis in breast cancer cells

Cytochrome c is a key component of the electron transport chain that is reported to translocate from the mitochondria to the cytosol in cells undergoing apoptosis. A significant increase in the level of cytochrome c expression was found in artemisinin treated cells as compared to control (Fig. 5a and b). The confocal image showed release of cytochrome c into the cytosol, which seemed to sequential caspase 9 activation. Caspase 9 is an important player in apoptosis. It is an initiator caspase playing important role in programmed cell death [86]. Caspase 9 cleavage acts as an apoptosis marker. Artemisinin treatment resulted in an enhanced cleavage of caspase 9 in MCF-7 breast cancer cells (Fig 5b).
Fig. 5
Fig. 5

Artemisinin induced apoptosis in MCF-7 cells is also through increased Cytochrome c release and Caspase 9 cleavage. a Confocal images of cytochrome c release. Cells stained with mitotracker DiOC6 [91], Cytochrome c (red), merged image shows Cytochrome c release (yellow). b Immunoblot against cytochrome c, and caspase 9 showing increased cleaved caspase 9

Artemisinin acts as an inhibitor for histone deacetylases (HDACs)

Recently, HDAC inhibitors have been investigated as possible target for cancer treatment. While exploring the possible modes of action of artemisinin in cancer cells, we checked the alteration in the expression of epigenetic modifiers HDACs in breast cancer cells upon its treatment. Upon artemisinin treatment, reduced level of HDACs was evidenced. HDAC 1, 2 and 6 were found to be decreased significantly in both the breast cancer cells MCF-7 and T47D (Fig. 6). In MDA-MB-231 cells, HDAC6 level was increased. Expression of HDAC 3 was different in cell types, was found to be increased in MCF-7 at the same time diminished in T47D and MDA-MB-231.
Fig. 6
Fig. 6

Artemisinin inhibits HDACs. A (I) Western blot assay with protein extracted from MCF-7, T47D and MDA-MB-231 cells treated with artemisinin. Immunoblot was developed using primary antibody HDAC 1, 2, 3 and 6. (II) Densitometry analysis of the protein levels of HDACs as observed in the western blot

Discussion

Studies have shown that artemisinin has a potent antimalarial and anticancer activity in many cancer cell lines in vitro [87] and in vivo [88], but its direct role in inhibiting breast cancer cell migration and invasion of breast cancer cells has not been studied in depth. Artemisinin treatment altered the expression of relevant genes involved in mammary gland development, cancer cell proliferation, migration, invasion and apoptosis. Our study shows that a dosage of 1 μM, which is of micromolar range and hence physiologically relevant, causes cancer cell growth inhibition. Migratory behavior of cancer cells have been shown to be related to metastasis, which has always been one of the major challenges in cancer treatment [89], also being one of the key target to improve a patient’s prognosis. Artemisinin induces anti-migratory and reduced invasive effect in breast cancer cells through master regulators such as cadherins and matrix metalloproteinases. Increased β-catenin cytoplasmic localization inhibited EMT in artemisinin treated MCF-7 breast cancer cells. Tumor growth is evident because of uncontrolled proliferation and reduced apoptosis. Thus, reduced proliferation and induction of cancer cell apoptosis is a key strategy in anticancer therapy [90]. Through cyclins and CDKs artemisinin inhibits cell proliferation. Inducing apoptosis contributes to cancer treatment through various mechanisms, inhibiting resistance to immune based cytotoxicity. In current study, role of increased Cytochrome c release and caspase 9 cleavage in artemisinin induced apoptosis was found which validated previous reports suggesting involvement of mitochondrial pathway of apoptosis upon artemisinin treatment in MCF-7 breast cancer cells. Also western blot assay evidenced artemisinin as HDAC inhibitor. HDAC 1, 2 and 6 were significantly reduced upon artemisinin treatment in breast cancer cells.

Conclusions

Taken together, our data apparently point out to the fact that in response to artimisinin treatment HDACs contributes towards altered expression of tumor suppressor genes and oncogenes resulting into reduced breast cancer cell proliferation, migration, invasion and increased apoptosis. Our data also suggest the role of epigenetics in anti-cancerous activity of artemisinin in cancer. Further exploration is required to establish the contribution of epigenetics in artemisinin-mediated reduced breast tumorigenesis. The obtained findings provide rational insight for the further evaluation of artemisinin as a safe, efficient and selective drug in the treatment and prevention of human breast cancer.

Abbreviations

7AAD: 

7-amino-actinomycin D

DMEM: 

Dulbecco’s Modified Eagle’s Medium

DMSO: 

Dimethyl Sulfoxide

EDTA: 

Ethylenediaminetetraacetic acid

ER: 

Endoplasmic reticulum

FBS: 

Fetal Bovine Serum

HRP: 

Horseradish peroxidase

IC50 : 

Median Inhibitory concentration

MTT: 

3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide

PBS: 

Phosphate buffered saline

PE: 

Phycoerythrin

PVDF: 

polyvinyl difluoride

RIPA: 

Radioimmunoprecipitation assay buffer

ROS: 

Reactive oxygen species

SDS-PAGE: 

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

TBST: 

Tris Buffered Saline with Tween® 20

TE: 

Tris- Ethylenediaminetetraacetic acid

Declarations

Acknowledgements

We acknowledge Department of Biotechnology, Govt of India and Department of Science and Technology, Govt. Of India for the funding. We also acknowledge the Director, Institute of Life Sciences, for the core grant as well as his support in carrying out the project. We express our gratitude to IPCA (International pharmaceutical company, Mumbai, India) for providing aetemisinin through Dr. S.C.Sabat.

Funding

DBT, Govt. of India. DST, Govt. of India

Availability of data and materials

All relevant raw data will be provided as per requirement.

Authors’ contributions

KK: Made substantial contributions to conception and design, acquisition, analysis, interpretation of data and manuscript preparation. SK, DS and SCS: Contributed in acquisition and interpretation of data. SKM: Overall guidance and manuscript preparation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

NA

Consent for publication

NA

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Cancer Biology Laboratory, Institute of Life Sciences (Government of India), Nalco Square, Bhubaneswar, Odisha, 751023, India
(2)
National Central University, Chungli, Taiwan
(3)
Molecular biology of abiotic stress, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, 751023, India
(4)
Department of Molecular Medicine, Bose Institute, Kolkata, India

References

  1. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res. 2003;533(1-2):153–71.View ArticlePubMedGoogle Scholar
  2. Kabat GC, Miller AB, Jain M, Rohan TE. A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women. Br J Cancer. 2007;97(1):118–22.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Wen CP, Lee JH, Tai YP, Wen C, SB W, Tsai MK, Hsieh DP, Chiang HC, Hsiung CA, Hsu CY, et al. High serum iron is associated with increased cancer risk. Cancer Res. 2014;74(22):6589–97.View ArticlePubMedGoogle Scholar
  4. Huang X. Does iron have a role in breast cancer? Lancet Oncol. 2008;9(8):803–7.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med. 1988;319(16):1047–52.View ArticlePubMedGoogle Scholar
  6. Stevens RG, Beasley RP, Blumberg BS. Iron-binding proteins and risk of cancer in Taiwan. J Natl Cancer Inst. 1986;76(4):605–10.View ArticlePubMedGoogle Scholar
  7. Wurzelmann JI, Silver A, Schreinemachers DM, Sandler RS, Everson RB. Iron intake and the risk of colorectal cancer. Cancer Epidemiol Biomark Prev. 1996;5(7):503–7.Google Scholar
  8. Paul I, Jones JM. Apoptosis block as a barrier to effective therapy in non small cell lung cancer. World J Clin Oncol. 2014;5(4):588–94.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, Kew MC. Dietary iron overload as a risk factor for hepatocellular carcinoma in black Africans. Hepatology. 1998;27(6):1563–6.View ArticlePubMedGoogle Scholar
  10. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001;18(4):767–73.PubMedGoogle Scholar
  11. Mercer AE, Maggs JL, Sun XM, Cohen GM, Chadwick J, O'Neill PM, Park BK. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem. 2007;282(13):9372–82.View ArticlePubMedGoogle Scholar
  12. Mercer AE, Copple IM, Maggs JL, O'Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem. 2011;286(2):987–96.View ArticlePubMedGoogle Scholar
  13. Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB. Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J. 2014;13:359.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Seo EJ, Wiench B, Hamm R, Paulsen M, Zu Y, Fu Y, Efferth T. Cytotoxicity of natural products and derivatives toward MCF-7 cell monolayers and cancer stem-like mammospheres. Phytomedicine Int J Phytotherapy Phytopharmacol. 2015;22(4):438–43.View ArticleGoogle Scholar
  15. Shahbazfar AA, Zare P, Ranjbaran M, Tayefi-Nasrabadi H, Fakhri O, Farshi Y, Shadi S, Khoshkerdar A. A survey on anticancer effects of artemisinin, iron, miconazole, and butyric acid on 5637 (bladder cancer) and 4T1 (breast cancer) cell lines. J Cancer Res Ther. 2014;10(4):1057–62.View ArticlePubMedGoogle Scholar
  16. Gong Y, Gallis BM, Goodlett DR, Yang Y, Lu H, Lacoste E, Lai H, Sasaki T. Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines. Anticancer Res. 2013;33(1):123–32.PubMedGoogle Scholar
  17. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH, Efferth T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One. 2007;2(8):e798.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Kim SH, Kang SH, Kang BS. Therapeutic effects of dihydroartemisinin and transferrin against glioblastoma. Nutr Res Prac. 2016;10(4):393–7.View ArticleGoogle Scholar
  19. Lai H, Nakase I, Lacoste E, Singh NP, Sasaki T. Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res. 2009;29(10):3807–10.PubMedGoogle Scholar
  20. Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 2001;70(1):49–56.View ArticlePubMedGoogle Scholar
  21. Ha VT, Kien VT, Binh le H, Tien VD, My NT, Nam NH, Baltas M, Hahn H, Han BW, Thao do T et al: Design, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton. Bioorg Chem 2016, 66:63-71.Google Scholar
  22. Li M, Jiang F, Yu X, Miao Z. Engineering isoprenoid biosynthesis in Artemisia Annua L. for the production of taxadiene: a key intermediate of taxol. Biomed Res Int. 2015;2015:504932.PubMedPubMed CentralGoogle Scholar
  23. Zuma NH, Smit FJ, de Kock C, Combrinck J, Smith PJ, N'Da DD. Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin. Eur J Med Chem. 2016;122:635–46.View ArticlePubMedGoogle Scholar
  24. Magoulas GE, Tsigkou T, Skondra L, Lamprou M, Tsoukala P, Kokkinogouli V, Pantazaka E, Papaioannou D, Athanassopoulos CM, Papadimitriou E. Synthesis of nomicronvel artemisinin dimers with polyamine linkers and evaluation of their potential as anticancer agents. Bioorg Med Chem. 2017;25(14):3756–67.View ArticlePubMedGoogle Scholar
  25. Noori S, Hassan ZM. Tehranolide inhibits proliferation of MCF-7 human breast cancer cells by inducing G0/G1 arrest and apoptosis. Free Radic Biol Med. 2012;52(9):1987–99.View ArticlePubMedGoogle Scholar
  26. Wang S, Sasaki T. Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells. Bioorg Med Chem Lett. 2013;23(15):4424–7.View ArticlePubMedGoogle Scholar
  27. Zuo ZZ, Zhong H, Cai T, Bao Y, Liu ZQ, Liu D, Zhao LX. Design, synthesis and antiproliferative activities of artemisinin derivatives substituted by N-heterocycles. Yao Xue Xue Bao Acta Pharmaceutica Sinica. 2015;50(7):868–74.PubMedGoogle Scholar
  28. Dadgar N, Alavi SE, Esfahani MK, Akbarzadeh A. Study of toxicity effect of pegylated nanoliposomal artemisinin on breast cancer cell line. Indian J Clin Biochem. 2013;28(4):410–2.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Dadgar N, Koohi Moftakhari Esfahani M, Torabi S, Alavi SE, Akbarzadeh A. Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer. Indian J Clin Biochem. 2014;29(4):501–4.View ArticlePubMedGoogle Scholar
  30. Gharib A, Faezizadeh Z, Mesbah-Namin SA, Saravani R. Experimental treatment of breast cancer-bearing BALB/c mice by artemisinin and transferrin-loaded magnetic nanoliposomes. Pharmacogn Mag. 2015;11(Suppl 1):S117–22.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Natesan S, Ponnusamy C, Sugumaran A, Chelladurai S, Shanmugam Palaniappan S, Palanichamy R. Artemisinin loaded chitosan magnetic nanoparticles for the efficient targeting to the breast cancer. Int J Biol Macromol. 2017;Google Scholar
  32. Tran TH, Nguyen AN, Kim JO, Yong CS, Nguyen CN. Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers. Artificial Cells, Nanomed Biotechnol. 2016;44(8):1979–87.View ArticleGoogle Scholar
  33. Tran TH, Nguyen TD, Poudel BK, Nguyen HT, Kim JO, Yong CS, Nguyen CN. Development and evaluation of Artesunate-loaded Chitosan-coated lipid Nanocapsule as a potential drug delivery system against breast cancer. AAPS PharmSciTech. 2015;16(6):1307–16.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Wang Z, Yu Y, Ma J, Zhang H, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. Mol Pharm. 2012;9(9):2646–57.View ArticlePubMedGoogle Scholar
  35. Jabbarzadegan M, Rajayi H, Mofazzal Jahromi MA, Yeganeh H, Yousefi M, Muhammad Hassan Z, Majidi J. Application of arteether-loaded polyurethane nanomicelles to induce immune response in breast cancer model. Artificial Cells Nanomed Biotechnol. 2017;45(4):808–16.View ArticleGoogle Scholar
  36. Zhang YJ, Gallis B, Taya M, Wang S, Ho RJ, Sasaki T. pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PLoS One. 2013;8(3):e59086.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Chen G, Gong R, Shi X, Yang D, Zhang G, Lu A, Yue J, Bian Z. Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. Oncotarget. 2016;7(31):50302–14.View ArticlePubMedPubMed CentralGoogle Scholar
  38. GS W, JJ L, Guo JJ, Huang MQ, Gan L, Chen XP, Wang YT. Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacological Reports. 2013;65(2):453–9.View ArticleGoogle Scholar
  39. Wang D, Zhao Y, Wang Y, Rong Y, Qin H, Bao Y, Song Z, Yu C, Sun L, Li Y. 25-methoxyl-dammarane-3beta, 12beta, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression. Tumour Biology. 2016;37(9):11805–13.View ArticlePubMedGoogle Scholar
  40. Li Q, Wang W, Liu Y, Lian B, Zhu Q, Yao L, Liu T. The biological characteristics of a novel camptothecin-artesunate conjugate. Bioorg Med Chem Lett. 2015;25(1):148–52.View ArticlePubMedGoogle Scholar
  41. Langroudi L, Hassan ZM, Ebtekar M, Mahdavi M, Pakravan N, Noori S. A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. Int Immunopharmacol. 2010;10(9):1055–61.View ArticlePubMedGoogle Scholar
  42. Suberu JO, Romero-Canelon I, Sullivan N, Lapkin AA, Barker GC. Comparative cytotoxicity of artemisinin and cisplatin and their interactions with chlorogenic acids in MCF7 breast cancer cells. ChemMedChem. 2014;9(12):2791–7.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Singh NP, Lai HC, Park JS, Gerhardt TE, Kim BJ, Wang S, Sasaki T. Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. Anticancer Res. 2011;31(12):4111–4.PubMedGoogle Scholar
  44. Tai X, Cai XB, Zhang Z, Wei R. In vitro and in vivo inhibition of tumor cell viability by combined dihydroartemisinin and doxorubicin treatment, and the underlying mechanism. Oncol Lett. 2016;12(5):3701–6.PubMedPubMed CentralGoogle Scholar
  45. Zhang YJ, Zhan X, Wang L, Ho RJ, Sasaki T. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model. J Pharm Sci. 2015;104(5):1815–24.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Osaki T, Uto Y, Ishizuka M, Tanaka T, Yamanaka N, Kurahashi T, Azuma K, Murahata Y, Tsuka T, Itoh N, et al. Artesunate enhances the Cytotoxicity of 5-Aminolevulinic acid-based Sonodynamic therapy against mouse mammary tumor cells in vitro. Molecules. 2017;22(4)Google Scholar
  47. Noori S, Hassan ZM. Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. Cell Immunol. 2011;271(1):67–72.View ArticlePubMedGoogle Scholar
  48. Farsam V, Hassan ZM, Zavaran-Hosseini A, Noori S, Mahdavi M, Ranjbar M. Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. Int Immunopharmacol. 2011;11(11):1802–8.View ArticlePubMedGoogle Scholar
  49. Lai H, Singh NP. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett. 2006;231(1):43–8.View ArticlePubMedGoogle Scholar
  50. Feng MX, Hong JX, Wang Q, Fan YY, Yuan CT, Lei XH, Zhu M, Qin A, Chen HX, Hong D. Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts. Sci Rep. 2016;6:19074.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Ericsson T, Blank A, von Hagens C, Ashton M, Abelo A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol. 2014;70(12):1453–63.View ArticlePubMedGoogle Scholar
  52. Konig M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Sertel S. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother Pharmacol. 2016;77(2):413–27.View ArticlePubMedGoogle Scholar
  53. Panossian LA, Garga NI, Pelletier D. Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann Neurol. 2005;58(5):812–3.View ArticlePubMedGoogle Scholar
  54. Hargraves KG, He L, Firestone GL. Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells. Mol Carcinog. 2016;55(5):486–98.View ArticlePubMedGoogle Scholar
  55. Odaka Y, Xu B, Luo Y, Shen T, Shang C, Wu Y, Zhou H, Huang S. Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis. 2014;35(1):192–200.View ArticlePubMedGoogle Scholar
  56. Lucibello M, Adanti S, Antelmi E, Dezi D, Ciafre S, Carcangiu ML, Zonfrillo M, Nicotera G, Sica L, De Braud F, et al. Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. Oncotarget. 2015;6(7):5275–91.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, Firestone GL. Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anti-Cancer Drugs. 2012;23(4):370–9.View ArticlePubMedGoogle Scholar
  58. Chen K, Shou LM, Lin F, Duan WM, MY W, Xie X, Xie YF, Li W, Tao M. Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Anti-Cancer Drugs. 2014;25(6):652–62.PubMedGoogle Scholar
  59. Sundar SN, Marconett CN, Doan VB, Willoughby JA Sr, Firestone GL. Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis. 2008;29(12):2252–8.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Hamacher-Brady A, Stein HA, Turschner S, Toegel I, Mora R, Jennewein N, Efferth T, Eils R, Brady NR. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem. 2011;286(8):6587–601.View ArticlePubMedGoogle Scholar
  61. Mao H, Gu H, Qu X, Sun J, Song B, Gao W, Liu J, Shao Q. Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. Int J Mol Med. 2013;31(1):213–8.View ArticlePubMedGoogle Scholar
  62. Bachmeier B, Fichtner I, Killian PH, Kronski E, Pfeffer U, Efferth T. Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One. 2011;6(5):e20550.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Qaderi A, Dadgar N, Mansouri H, Alavi SE, Esfahani MK, Akbarzadeh A. Modeling and prediction of cytotoxicity of artemisinin for treatment of the breast cancer by using artificial neural networks. SpringerPlus. 2013;2:340.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Chekhun VF, Lukianova NY, Borikun TV, Zadvorny TV, Mokhir A. Artemisinin modulating effect on human breast cancer cell lines with different sensitivity to cytostatics. Exp Oncol. 2017;39(1):25–9.PubMedGoogle Scholar
  65. Zhong H, Zhao X, Zuo Z, Sun J, Yao Y, Wang T, Liu D, Zhao L. Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells. Eur J Med Chem. 2016;108:720–9.View ArticlePubMedGoogle Scholar
  66. Sagar S, Esau L, Moosa B, Khashab NM, Bajic VB, Kaur M. Cytotoxicity and apoptosis induced by a plumbagin derivative in estrogen positive MCF-7 breast cancer cells. Anti Cancer Agents Med Chem. 2014;14(1):170–80.View ArticleGoogle Scholar
  67. Lemmo S, Nasrollahi S, Tavana H. Aqueous biphasic cancer cell migration assay enables robust, high-throughput screening of anti-cancer compounds. Biotechnol J. 2014;9(3):426–34.View ArticlePubMedGoogle Scholar
  68. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39(3):305–18.View ArticlePubMedGoogle Scholar
  69. Stein RA, Chang CY, Kazmin DA, Way J, Schroeder T, Wergin M, Dewhirst MW, McDonnell DP. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res. 2008;68(21):8805–12.View ArticlePubMedPubMed CentralGoogle Scholar
  70. Kim JH, Choi YK, Byun JK, Kim MK, Kang YN, Kim SH, Lee S, Jang BK, Park KG. Estrogen-related receptor gamma is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27. Exp Mol Med. 2016;48:e213.View ArticlePubMedPubMed CentralGoogle Scholar
  71. Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene. 2015;34(4):506–15.View ArticlePubMedGoogle Scholar
  72. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 2001;142(9):4120–30.View ArticlePubMedPubMed CentralGoogle Scholar
  73. Dai M, Al-Odaini AA, Fils-Aime N, Villatoro MA, Guo J, Arakelian A, Rabbani SA, Ali S, Lebrun JJ. Cyclin D1 cooperates with p21 to regulate TGFbeta-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res. 2013;15(3):R49.View ArticlePubMedPubMed CentralGoogle Scholar
  74. Ramsey B, Bai T, Hanlon Newell A, Troxell M, Park B, Olson S, Keenan E, Luoh SW. GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res Treat. 2011;127(3):659–69.View ArticlePubMedGoogle Scholar
  75. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114(Pt 16):2903–10.PubMedGoogle Scholar
  76. Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539–52.View ArticlePubMedPubMed CentralGoogle Scholar
  77. Qiu M, Bao W, Wang J, Yang T, He X, Liao Y, Wan X. FOXA1 promotes tumor cell proliferation through AR involving the notch pathway in endometrial cancer. BMC Cancer. 2014;14:78.View ArticlePubMedPubMed CentralGoogle Scholar
  78. Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer. 2010;1(6):629–40.View ArticlePubMedPubMed CentralGoogle Scholar
  79. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220–7.View ArticlePubMedGoogle Scholar
  80. Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguere V, Siegel PM, Bouchard M. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene. 2009;28(29):2634–42.View ArticlePubMedGoogle Scholar
  81. Lu XX, Cao LY, Chen X, Xiao J, Zou Y, Chen Q. PTEN inhibits cell proliferation, promotes cell apoptosis, and induces cell cycle arrest via Downregulating the PI3K/AKT/hTERT pathway in lung Adenocarcinoma A549 cells. Biomed Res Int. 2016;2016:2476842.PubMedPubMed CentralGoogle Scholar
  82. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994;1198(1):11–26.PubMedGoogle Scholar
  83. Lebrun JJ. The dual role of TGFbeta in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol. 2012;2012:381428.View ArticlePubMedPubMed CentralGoogle Scholar
  84. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. Beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A. 2011;108(48):19204–9.View ArticlePubMedPubMed CentralGoogle Scholar
  85. Das AK. Anticancer effect of AntiMalarial Artemisinin compounds. Ann Med Health Sci Res. 2015;5(2):93–102.View ArticlePubMedPubMed CentralGoogle Scholar
  86. Wurstle ML, Laussmann MA, Rehm M. The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res. 2012;318(11):1213–20.View ArticlePubMedGoogle Scholar
  87. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res. 2003;48(3):231–6.View ArticlePubMedGoogle Scholar
  88. Lombard MC, N'Da DD, Breytenbach JC, Kolesnikova NI, Tran Van Ba C, Wein S, Norman J, Denti P, Vial H, Wiesner L. Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice. Eur J Pharm Sci. 2012;47(5):834–41.View ArticlePubMedGoogle Scholar
  89. KW L, Chen JC, Lai TY, Yang JS, Weng SW, Ma YS, PJ L, Weng JR, Chueh FS, Wood WG, et al. Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2 -9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways. Hum Exp Toxicol. 2011;30(5):406–15.View ArticleGoogle Scholar
  90. Zhou QM, Wang XF, Liu XJ, Zhang H, YY L, Huang S, SB S. Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. Eur J Cancer. 2011;47(14):2240–7.View ArticlePubMedGoogle Scholar
  91. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem. 1999;274(4):2225–33.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us